The U.S. Food and Drug Administration has approved Firdapse, a new medicine developed by Coral Gables-based Catalyst Pharmaceuticals.
The biopharmaceutical company (Nasdaq: CPRX) expects the drug to be commercially available in the first quarter of 2019. It was designed to treat Lambert-Eaton Myasthenic Syndrome, a rare autoimmune disease that causes muscle weakness and fatigue.
